

trated in that area and this leads to the progression of joint destruction.

Our present results indicated the possibility that joint destruction in the RA elbow begins on the radial side of the humeral trochlea and gradually spreads mediolaterally. If we accept the validity of this pattern of destruction of the elbow joint, then when analyzing X-rays taken in the early stage of RA elbow joint damage, it should be possible to focus on the radial side of the humeral trochlea and determine whether joint destruction had already begun. In addition, if bone destruction on the radial side of the trochlea were mild, we would be able to conclude that the joint destruction was at an early stage and that a minimally invasive therapy such as synovectomy was indicated.

The progression of joint destruction can be considered influenced by various factors, such as medication (including NSAIDs, DMARDs, and steroids), disease duration, and progression of joint deformation due to aging or osteoporosis [16–19]. A limitation of the present study was that we were unable to discuss the possible effects of drug treatments, disease duration, and aging in our patient series. However, this is the first report of a statistical analysis of the pattern of joint destruction in the rheumatoid elbow, and we think that our findings will make a significant contribution to decision making regarding therapeutic approaches to RA of the elbow.

References

1. Boyd AD, Thornhill TS (1989) Surgical treatment of the elbow in rheumatoid arthritis. *Hand Clin* 5(4):645–655
2. Rosenberg GM, Tuner RH (1984) Nonconstrained total elbow arthroplasty. *Clin Orthop* 187:154–162
3. Linclau LA, Winia WPCA, Korst JK (1983) Synovectomy of the elbow in rheumatoid arthritis. *Acta Orthop Scand* 54(6):935–937
4. Pritchard RW (1991) Total elbow joint arthroplasty in patients with rheumatoid arthritis. *Semin Arthritis Rheum* 21(1):24–29
5. Ljung P, Jonsson K, Rydgren L, Rydholm U (1995) The natural course of rheumatoid elbow arthritis: a radiographic and clinical five-year follow up. *J Orthop Rheumatol* 8:332–36
6. Lehtinen JT, Kaarela K, Kauppi MJ, Belt EA, Maenpaa HM, Lehto MUK (2002) Bone destruction patterns of the rheumatoid elbow: a radiographic assessment of 148 elbows at 15 years. *J Shoulder Elbow Surg* 11:253–258
7. Lehtinen JT, Kaarela K, Belt EA, Kauppi MJ, Skytta E, Kuusela PP, Kautiainen HJ, Lehto MUK (2001) Radiographic joint space in rheumatoid elbow joints. A 15-year prospective follow-up study in 74 patients. *Rheumatology* 40:1141–1145
8. Kirwan JR (1997) The relationship between synovitis and erosions in rheumatoid arthritis. *Br J Rheumatol* 36:225–228
9. Cuomo F, Greller MJ, Zuckerman JD (1998) The rheumatoid shoulder. *Rheum Dis Clin North Am* 24:67–82
10. Tan AL, Tanner SF, Conaghan PG, Radjenovic A, O'Connor P, Brown AK, Emery P, McGonagle D (2003) Role of metacarpophalangeal joint anatomic factors in the distribution of synovitis and bone erosion in early rheumatoid arthritis. *Arthritis Rheum* 48:1214–1222
11. Ochi T, Iwase R, Yonemasu K, Matsukawa M, Yoneda M, Yukioka M, Ono K (1988) Natural course of joint destruction and fluctuation of serum C1q levels in patients with arthritis. *Arthritis Rheum* 31:37–43
12. Amis AA, Dowson D, Wright V, Miller JH (1979) The derivation of the elbow joint forces and their relation to prosthesis design. *J Med Eng Technol* 3:229–234
13. Amis AA, Dowson D, Wright V (1980) Elbow joint force predictions for some strenuous isometric actions. *J Biomech* 13:765–775
14. Halls AA, Travill R (1964) Transmission of pressure across the elbow joint. *Anat Rec* 150:243–247
15. Morrey BF, An KN, Stormont TJ (1988) Force transmission through the radial head. *J Bone Jt Surg* 70-A:250–256
16. McIlwain HH (2003) Glucocorticoid-induced osteoporosis: pathogenesis, diagnosis, and management. *Prev Med* 36:243–249
17. Solomon DH, Levin Elaine, Helfgott SM (2000) Patterns of medication use before and after bone densitometry: factors associated with appropriate treatment. *J Rheumatol* 27:1496–1500
18. Minaur NJ, Kounail D, Vedi S, Compston JE, Beresford JN, Bhalla K (2002) Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. *Rheumatology* 41:741–749
19. Dolan AL, Moniz C, Abraha H, Pitt P (2002) Does active treatment of rheumatoid arthritis limit disease-associated bone loss? *Rheumatology* 41:1041–1047